Barclays PLC Cuts Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Barclays PLC decreased its stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,523 shares of the company's stock after selling 69,249 shares during the quarter. Barclays PLC's holdings in Bausch Health Companies were worth $754,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Tobam raised its position in Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after purchasing an additional 1,422 shares during the last quarter. Wells Fargo & Company MN raised its stake in Bausch Health Companies by 7.9% during the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after acquiring an additional 1,896 shares during the last quarter. American Century Companies Inc. raised its stake in Bausch Health Companies by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock valued at $220,000 after acquiring an additional 2,600 shares during the last quarter. Blair William & Co. IL raised its stake in Bausch Health Companies by 3.2% during the 4th quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock valued at $683,000 after acquiring an additional 2,622 shares during the last quarter. Finally, Sanders Morris Harris LLC raised its stake in shares of Bausch Health Companies by 16.0% during the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after buying an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.

Bausch Health Companies Price Performance

NYSE:BHC traded up $0.23 during trading hours on Monday, reaching $4.82. 1,897,701 shares of the company traded hands, compared to its average volume of 2,628,045. The firm's 50-day moving average is $5.79 and its 200-day moving average is $7.09. The stock has a market cap of $1.74 billion, a P/E ratio of -40.29, a P/E/G ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. As a group, research analysts predict that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Analyst Ratings Changes

BHC has been the subject of a number of analyst reports. StockNews.com downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday. Royal Bank of Canada upped their price target on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat.com, Bausch Health Companies presently has an average rating of "Hold" and a consensus target price of $7.42.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.